We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4768:TSEOTSUKA CORPORATION Analysis

Data as of 2026-06-12 - not real-time

₩92,300.00

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Rznomics is trading at 92,300 KRW, well below its 20‑day (121,225), 50‑day (160,056) and 200‑day (161,732) simple moving averages, signaling a strong bearish momentum. The MACD line sits beneath its signal line with a negative histogram, and the RSI is at 27, indicating the stock is oversold but still in a downtrend. Volume is decreasing, and the 30‑day volatility is a lofty 87%, while a beta of 1.5 points to amplified market swings. The price sits near the identified support of 83,000 KRW and far from the resistance at 157,600 KRW, with a historical max drawdown of nearly 63%. Technical indicators suggest limited short‑term upside, yet the extreme‑greed market sentiment may tempt speculative buying. Fundamentally, the company reports zero revenue and earnings, offering no traditional valuation anchors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish trend with price below all major moving averages
  • Decreasing volume and negative MACD histogram
  • Price approaching immediate support level

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Oversold RSI suggesting potential rebound
  • Potential catalyst from upcoming Phase 1/2 trial results
  • Extreme‑greed market sentiment may provide buying pressure

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • High growth potential of RNA‑based gene therapies
  • Long‑term upside in biotechnology sector despite current lack of revenue
  • Strategic positioning in multiple high‑need disease areas

Key Metrics & Analysis

Financial Health

Industry P/E24.9

Technical Analysis

TrendBearish
RSI27.2
Support₩83,000.00
Resistance₩157,600.00
MA 20₩121,225.00
MA 50₩160,056.00
MA 200₩161,732.17
MACDBearish
VolumeDecreasing
Fear & Greed Index87.07

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.50
Volatility87.10%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.